SparingVision FFB

Established in 1971, the Foundation Fighting Blindness is the world’s leading private funding source for retinal degenerative disease research. The Foundation has raised more than $800 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease.

 

SparingVision FVE

Created in May 2007, the Foundation"Voir et Entendre"'s challenges are to defy sensory handicaps linked to vision and hearing, both of which have become public health stakes. As we can see throughout industrialized countries ocular and auditory diseases are gaining ground, mainly due to the ageing populations.
The Foundation therefore brings together the best-known French and international scientific teams, hospital services and industries around common research themes, with the aim to rapidly find new and adapted treatments.
Within the Foundation is the research center “Vision Institute” managed by José-Alain Sahel, the Clinical Investigation Centre of the National Ophthalmologic Hospital Centre (CHNO) of the Quinze-Vingts, reference centers for rare diseases and four clinical hospital departments.
The head office is located at the Vision Institute, itself within the CHNO of the Quinze-Vingts in Paris. The latter has supported this project from the outset along with the Pasteur Institute, National Institute of Health and Medical Research (INSERM), Pierre and Marie Curie University and the French Federation of the Blind and Visually Impaired.

SparingVision retine inter

Retina International (RI) was formed in 1978 to deliver the most up to date information on retinal research and development to its membership all over the world. RI is a global umbrella organisation for patient-led charities and foundations who support research into rare, genetically inherited and age-related forms of retinal disease. The organisation works with all its stakeholders to develop the tools to enable robust health and research policies to improve the lives of all affected by retinal disease, wherever they live.